Veradermics, Inc.
Clinical trials sponsored by Veradermics, Inc., explained in plain language.
-
Baldness breakthrough? new pill VDPHL01 heads to final testing
Disease control OngoingThis study tests a new daily pill, VDPHL01, for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 13 months. The main goal is to see if the drug increases hair count and if partici…
Phase: PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New hair loss pill shows promise in early trial
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for people with mild to moderate pattern baldness (androgenetic alopecia). About 70 men and women aged 18-65 will take the pill daily for 12 months to see if it safely increases hair count and improves appearance. The drug…
Phase: PHASE2 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New pill could help men regrow hair
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…
Phase: PHASE2, PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC